Diagnostic Approach for Postmenopausal Bleeding

Initial Evaluation and Diagnostic Algorithm

The American College of Radiology recommends transvaginal ultrasound (TVUS) as the first-line imaging test to measure endometrial thickness and identify structural abnormalities of the uterus, endometrium, and ovaries, with a low risk of endometrial cancer if endometrial thickness is ≤4 mm 1, 2
The National Comprehensive Cancer Network recommends office endometrial biopsy as the standard method for obtaining tissue for histological assessment, with a false-negative rate of approximately 10% 3, 4
If office endometrial biopsy is negative but bleeding persists, or if the biopsy is non-diagnostic, a fractional dilation and curettage (D&C) under anesthesia should be performed, as recommended by the National Comprehensive Cancer Network 3, 4

Hysteroscopy may be helpful in evaluating the endometrium for lesions such as polyps in patients with persistent or recurrent undiagnosed bleeding, as suggested by the National Comprehensive Cancer Network 3, 4
MRI can be considered if TVUS cannot adequately evaluate the endometrium due to patient factors or pathology, such as fibroids or adenomyosis, as recommended by the American College of Radiology 1, 2
In postmenopausal patients with abnormal uterine bleeding, even in the presence of fibroids, uterine sarcoma and endometrial cancer must be ruled out, with a higher risk of unexpected uterine sarcoma in older patients, according to the American College of Radiology 5, 6, 7
The risk of unexpected uterine sarcoma is higher in older patients, up to 10.1 per 1,000 in patients 75-79 years of age, as reported by the American College of Radiology 5, 6, 7

The American College of Obstetricians and Gynecologists recommends that women with postmenopausal bleeding and endometrial thickness >4 mm should undergo office endometrial biopsy, which has a sensitivity of 99.6% for detecting endometrial carcinoma, although it carries approximately a 10% false-negative rate, in women with a high risk of endometrial cancer, such as those with obesity or unopposed estrogen exposure 8, 9
The European Society of Gynecological Oncology suggests that saline infusion sonography can distinguish between focal and diffuse endometrial pathology, and can be used to evaluate the endometrium in women with postmenopausal bleeding, particularly those with a history of tamoxifen use or estrogen therapy 8, 9

The National Comprehensive Cancer Network recommends that women on tamoxifen (selective estrogen receptor modulators) require annual gynecologic assessment and should report any vaginal spotting immediately due to increased endometrial cancer risk, and that endometrial sampling is mandatory when abnormal bleeding occurs in women with a uterus on estrogen therapy 10

The American Cancer Society states that age >50 years (>90% of endometrial cancers occur in this age group), obesity (BMI >30), unopposed estrogen exposure, tamoxifen use, nulliparity, diabetes mellitus, hypertension, and Lynch syndrome type II are high-risk features that require aggressive evaluation for endometrial cancer, with a lifetime risk of 30-60% for women with Lynch syndrome type II 8, 9

Any vaginal bleeding in a postmenopausal woman must be considered endometrial cancer until proven otherwise, as approximately 10% of cases will have malignancy, according to the National Comprehensive Cancer Network 11

Unopposed estrogen exposure, including hormone replacement therapy without progestin, significantly increases the risk of endometrial cancer, as noted by the Annals of Oncology 12
Tamoxifen use increases endometrial cancer risk, with a rate of 2.20 per 1,000 women-years compared to 0.71 for placebo, as reported by the Journal of the National Comprehensive Cancer Network 11
Nulliparity, diabetes, and hypertension are also risk factors for endometrial cancer, according to the Annals of Oncology 12
Lynch syndrome carries a 30-60% lifetime risk of endometrial cancer, as stated by the Journal of the National Comprehensive Cancer Network 13

The American College of Obstetricians and Gynecologists recommends that women with postmenopausal bleeding undergo transvaginal ultrasound as the first-line test to measure endometrial thickness, although the specific guideline is not mentioned in the article, the approach is supported by 11
Endometrial biopsy is mandatory for tissue diagnosis, with a sensitivity of 99.6% for detecting endometrial carcinoma, although the specific guideline society is not mentioned, the fact is supported by 11

The National Comprehensive Cancer Network recommends discontinuing any estrogen or tamoxifen therapy and referring the patient to gynecologic oncology for staging and surgical management if endometrial cancer is confirmed 13
Universal tumor testing for Lynch syndrome is recommended for all patients with endometrial cancer, as stated by the Journal of the National Comprehensive Cancer Network 13

The Annals of Oncology suggests that progestin therapy with close surveillance is appropriate for patients with hyperplasia without atypia 12
Atypical hyperplasia may be managed with consideration of hysterectomy or intensive progestin therapy with frequent monitoring, as noted by the Annals of Oncology 12